This is good news. I’ve been hoping for CYDY to start this trial for many years because of the promising preclinical results and MOA of leronlimab. Instead, the money was spent on Red Chip conference calls and interviews that only current investors watch. I digress.

Unlike the cancer trial(s), it looks like we won’t see any official updates from the GvHD trial until 10 patients have been treated for at least 30 days. Hopefully enrollment is quicker than that of the cancer trials or we may be waiting until the end of the year to get results. Either way, the trial has finally stated and is another possible indication to partner for (I know, I’m dreaming).

“The next review of data by the independent data monitoring committee (iDMC) will occur following enrollment of 10 patients under the amended protocol after each patient has been dosed for 30 days.”